ID   FCG3A_HUMAN             Reviewed;         254 AA.
AC   P08637; A2N6W9; Q53FJ0; Q53FL6; Q5EBR4; Q65ZM6; Q6PIJ0;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 2.
DT   07-APR-2021, entry version 216.
DE   RecName: Full=Low affinity immunoglobulin gamma Fc region receptor III-A;
DE   AltName: Full=CD16a antigen;
DE   AltName: Full=Fc-gamma RIII-alpha;
DE            Short=Fc-gamma RIII;
DE            Short=Fc-gamma RIIIa;
DE            Short=FcRIII;
DE            Short=FcRIIIa;
DE   AltName: Full=FcR-10;
DE   AltName: Full=IgG Fc receptor III-2;
DE   AltName: CD_antigen=CD16a;
DE   Flags: Precursor;
GN   Name=FCGR3A; Synonyms=CD16A, FCG3, FCGR3, IGFR3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2526846; DOI=10.1084/jem.170.2.481;
RA   Ravetch J.V., Perussia B.;
RT   "Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer
RT   cells and neutrophils. Cell type-specific expression of two genes that
RT   differ in single nucleotide substitutions.";
RL   J. Exp. Med. 170:481-497(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=16951347; DOI=10.4049/jimmunol.177.6.3848;
RA   Rogers K.A., Scinicariello F., Attanasio R.;
RT   "IgG Fc receptor III homologues in nonhuman primate species: genetic
RT   characterization and ligand interactions.";
RL   J. Immunol. 177:3848-3856(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-176.
RC   TISSUE=Synovium;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-176.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-39.
RC   TISSUE=Placenta;
RX   PubMed=7836402; DOI=10.1074/jbc.270.3.1350;
RA   Gessner J.E., Grussenmeyer T., Kolanus W., Schmidt R.E.;
RT   "The human low affinity immunoglobulin G Fc receptor III-A and III-B genes.
RT   Molecular characterization of the promoter regions.";
RL   J. Biol. Chem. 270:1350-1361(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 22-254, AND VARIANT VAL-176.
RX   PubMed=7700021; DOI=10.1038/ki.1994.462;
RA   Morcos M., Hansch G.M., Schonermark M., Ellwanger S., Harle M.,
RA   Heckl-Ostreicher B.;
RT   "Human glomerular mesangial cells express CD16 and may be stimulated via
RT   this receptor.";
RL   Kidney Int. 46:1627-1634(1994).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 31-254.
RC   TISSUE=Lung;
RX   PubMed=2525780; DOI=10.1073/pnas.86.13.5079;
RA   Scallon B.J., Scigliano E., Freedman V.H., Miedel M.C., Pan Y.C.,
RA   Unkeless J.C., Kochan J.P.;
RT   "A human immunoglobulin G receptor exists in both polypeptide-anchored and
RT   phosphatidylinositol-glycan-anchored forms.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:5079-5083(1989).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 21-193 IN COMPLEX WITH IGHG1,
RP   FUNCTION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-63 AND ASN-180.
RX   PubMed=22023369; DOI=10.1111/j.1365-2443.2011.01552.x;
RA   Mizushima T., Yagi H., Takemoto E., Shibata-Koyama M., Isoda Y., Iida S.,
RA   Masuda K., Satoh M., Kato K.;
RT   "Structural basis for improved efficacy of therapeutic antibodies on
RT   defucosylation of their Fc glycans.";
RL   Genes Cells 16:1071-1080(2011).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 19-208 IN COMPLEX WITH IGHG1,
RP   FUNCTION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-63 AND ASN-180.
RX   PubMed=21768335; DOI=10.1073/pnas.1108455108;
RA   Ferrara C., Grau S., Jager C., Sondermann P., Brunker P., Waldhauer I.,
RA   Hennig M., Ruf A., Rufer A.C., Stihle M., Umana P., Benz J.;
RT   "Unique carbohydrate-carbohydrate interactions are required for high
RT   affinity binding between FcgammaRIII and antibodies lacking core fucose.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:12669-12674(2011).
RN   [11]
RP   INVOLVEMENT IN IMD20, VARIANT IMD20 HIS-66, AND VARIANT ARG-66.
RX   PubMed=8609432;
RA   de Haas M., Koene H.R., Kleijer M., de Vries E., Simsek S., van Tol M.J.D.,
RA   Roos D., von dem Borne A.E.G.K.;
RT   "A triallelic Fc gamma receptor type IIIA polymorphism influences the
RT   binding of human IgG by NK cell Fc gamma RIIIa.";
RL   J. Immunol. 156:2948-2955(1996).
RN   [12]
RP   VARIANT VAL-176.
RX   PubMed=9242542;
RA   Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E.G.K.,
RA   de Haas M.;
RT   "Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural
RT   killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H
RT   phenotype.";
RL   Blood 90:1109-1114(1997).
RN   [13]
RP   VARIANT VAL-176.
RX   PubMed=9276722; DOI=10.1172/jci119616;
RA   Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K.,
RA   Salmon J.E., Kimberly R.P.;
RT   "A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and
RT   predisposes to autoimmune disease.";
RL   J. Clin. Invest. 100:1059-1070(1997).
RN   [14]
RP   INVOLVEMENT IN IMD20, AND VARIANT IMD20 HIS-66.
RX   PubMed=8874200;
RA   de Vries E., Koene H.R., Vossen J.M., Gratama J.W., von dem Borne A.E.,
RA   Waaijer J.L., Haraldsson A., de Haas M., van Tol M.J.;
RT   "Identification of an unusual Fc gamma receptor IIIa (CD16) on natural
RT   killer cells in a patient with recurrent infections.";
RL   Blood 88:3022-3027(1996).
RN   [15]
RP   VARIANT IMD20 HIS-66.
RX   PubMed=8608639; DOI=10.1111/j.1365-2249.1996.tb08295.x;
RA   Jawahar S., Moody C., Chan M., Finberg R., Geha R., Chatila T.;
RT   "Natural Killer (NK) cell deficiency associated with an epitope-deficient
RT   Fc receptor type IIIA (CD16-II).";
RL   Clin. Exp. Immunol. 103:408-413(1996).
RN   [16]
RP   VARIANT IMD20 HIS-66.
RX   PubMed=23006327; DOI=10.1172/jci64837;
RA   Grier J.T., Forbes L.R., Monaco-Shawver L., Oshinsky J., Atkinson T.P.,
RA   Moody C., Pandey R., Campbell K.S., Orange J.S.;
RT   "Human immunodeficiency-causing mutation defines CD16 in spontaneous NK
RT   cell cytotoxicity.";
RL   J. Clin. Invest. 122:3769-3780(2012).
CC   -!- FUNCTION: Receptor for the Fc region of IgG. Binds complexed or
CC       aggregated IgG and also monomeric IgG. Mediates antibody-dependent
CC       cellular cytotoxicity (ADCC) and other antibody-dependent responses,
CC       such as phagocytosis. {ECO:0000269|PubMed:21768335,
CC       ECO:0000269|PubMed:22023369}.
CC   -!- SUBUNIT: Exists as a heterooligomeric receptor complex with Fc epsilon
CC       receptor I gamma subunit and / or the CD3 zeta subunit. Interacts with
CC       INPP5D/SHIP1 (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type I
CC       membrane protein {ECO:0000305}. Secreted. Note=Exists also as a soluble
CC       receptor.
CC   -!- TISSUE SPECIFICITY: Expressed on natural killer cells, macrophages,
CC       subpopulation of T-cells, immature thymocytes and placental
CC       trophoblasts.
CC   -!- PTM: Glycosylated. Contains high mannose- and complex-type
CC       oligosaccharides. Glycosylation at Asn-180 is mandatory for high
CC       affinity binding to the Fc and for discrimination between fucosylated
CC       and afucosylated IgG glycoforms. {ECO:0000269|PubMed:21768335,
CC       ECO:0000269|PubMed:22023369}.
CC   -!- PTM: The soluble form is produced by a proteolytic cleavage.
CC   -!- DISEASE: Immunodeficiency 20 (IMD20) [MIM:615707]: A rare autosomal
CC       recessive primary immunodeficiency characterized by functional
CC       deficiency of NK cells. Affected individuals typically present with
CC       severe herpes viral infections, particularly Epstein Barr virus (EBV),
CC       and human papillomavirus (HPV). {ECO:0000269|PubMed:23006327,
CC       ECO:0000269|PubMed:8608639, ECO:0000269|PubMed:8609432,
CC       ECO:0000269|PubMed:8874200}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Encoded by one of two nearly indentical genes: FCGR3A
CC       (Shown here) and FCGR3B which are expressed in a tissue-specific
CC       manner. The Phe-203 in III-A determines the transmembrane domains
CC       whereas the 'Ser-203' in III-B determines the GPI-anchoring.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD96988.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAD97015.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=FCGR3Abase; Note=FCGR3A mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/FCGR3Abase/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X52645; CAA36870.1; -; mRNA.
DR   EMBL; AK223268; BAD96988.1; ALT_INIT; mRNA.
DR   EMBL; AK223295; BAD97015.1; ALT_INIT; mRNA.
DR   EMBL; AL590385; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017865; AAH17865.1; -; mRNA.
DR   EMBL; BC033678; AAH33678.1; -; mRNA.
DR   EMBL; Z46222; CAA86295.1; -; Genomic_DNA.
DR   EMBL; S76824; AAB33925.2; -; mRNA.
DR   EMBL; M24853; AAA53506.1; -; mRNA.
DR   CCDS; CCDS1232.2; -.
DR   CCDS; CCDS44266.1; -.
DR   PIR; JL0107; JL0107.
DR   RefSeq; NP_000560.6; NM_000569.7.
DR   RefSeq; NP_001121064.2; NM_001127592.2.
DR   RefSeq; NP_001121065.1; NM_001127593.1.
DR   RefSeq; NP_001121067.1; NM_001127595.1.
DR   RefSeq; NP_001121068.1; NM_001127596.1.
DR   RefSeq; NP_001316049.1; NM_001329120.1.
DR   PDB; 3AY4; X-ray; 2.20 A; C=21-193.
DR   PDB; 3SGJ; X-ray; 2.20 A; C=19-208.
DR   PDB; 3SGK; X-ray; 2.40 A; C=19-208.
DR   PDB; 3WN5; X-ray; 2.78 A; C/F=18-208.
DR   PDB; 5BW7; X-ray; 3.00 A; C=21-193.
DR   PDB; 5D6D; X-ray; 3.13 A; C=14-205.
DR   PDB; 5ML9; X-ray; 2.35 A; A=19-193.
DR   PDB; 5MN2; X-ray; 2.35 A; A/B=19-193.
DR   PDB; 5VU0; X-ray; 2.26 A; C=22-192.
DR   PDB; 5XJE; X-ray; 2.40 A; C=21-193.
DR   PDB; 5XJF; X-ray; 2.50 A; C=21-193.
DR   PDB; 5YC5; X-ray; 2.71 A; C=19-193.
DR   PDBsum; 3AY4; -.
DR   PDBsum; 3SGJ; -.
DR   PDBsum; 3SGK; -.
DR   PDBsum; 3WN5; -.
DR   PDBsum; 5BW7; -.
DR   PDBsum; 5D6D; -.
DR   PDBsum; 5ML9; -.
DR   PDBsum; 5MN2; -.
DR   PDBsum; 5VU0; -.
DR   PDBsum; 5XJE; -.
DR   PDBsum; 5XJF; -.
DR   PDBsum; 5YC5; -.
DR   SMR; P08637; -.
DR   BioGRID; 108508; 19.
DR   IntAct; P08637; 7.
DR   STRING; 9606.ENSP00000356946; -.
DR   ChEMBL; CHEMBL3856162; -.
DR   DrugBank; DB00092; Alefacept.
DR   DrugBank; DB00087; Alemtuzumab.
DR   DrugBank; DB12023; Benralizumab.
DR   DrugBank; DB00112; Bevacizumab.
DR   DrugBank; DB06607; Catumaxomab.
DR   DrugBank; DB00002; Cetuximab.
DR   DrugBank; DB00111; Daclizumab.
DR   DrugBank; DB00005; Etanercept.
DR   DrugBank; DB00056; Gemtuzumab ozogamicin.
DR   DrugBank; DB00028; Human immunoglobulin G.
DR   DrugBank; DB00110; Palivizumab.
DR   DrugBank; DB11767; Sarilumab.
DR   GuidetoPHARMACOLOGY; 3017; -.
DR   GlyGen; P08637; 6 sites.
DR   iPTMnet; P08637; -.
DR   PhosphoSitePlus; P08637; -.
DR   BioMuta; FCGR3A; -.
DR   DMDM; 119876; -.
DR   jPOST; P08637; -.
DR   MassIVE; P08637; -.
DR   PaxDb; P08637; -.
DR   PeptideAtlas; P08637; -.
DR   PRIDE; P08637; -.
DR   ProteomicsDB; 52146; -.
DR   TopDownProteomics; P08637; -.
DR   ABCD; P08637; 2 sequenced antibodies.
DR   Antibodypedia; 20512; 2293 antibodies.
DR   DNASU; 2214; -.
DR   Ensembl; ENST00000367967; ENSP00000356944; ENSG00000203747.
DR   Ensembl; ENST00000436743; ENSP00000416607; ENSG00000203747.
DR   Ensembl; ENST00000443193; ENSP00000392047; ENSG00000203747.
DR   GeneID; 2214; -.
DR   KEGG; hsa:2214; -.
DR   UCSC; uc001gat.5; human.
DR   CTD; 2214; -.
DR   DisGeNET; 2214; -.
DR   GeneCards; FCGR3A; -.
DR   HGNC; HGNC:3619; FCGR3A.
DR   HPA; ENSG00000203747; Tissue enhanced (blood, lymphoid tissue).
DR   MalaCards; FCGR3A; -.
DR   MIM; 146740; gene.
DR   MIM; 615707; phenotype.
DR   neXtProt; NX_P08637; -.
DR   OpenTargets; ENSG00000203747; -.
DR   Orphanet; 437552; Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity.
DR   PharmGKB; PA28065; -.
DR   VEuPathDB; HostDB:ENSG00000203747.9; -.
DR   eggNOG; ENOG502RU1M; Eukaryota.
DR   GeneTree; ENSGT01020000230518; -.
DR   HOGENOM; CLU_023383_1_0_1; -.
DR   InParanoid; P08637; -.
DR   OMA; GDNSTQW; -.
DR   OrthoDB; 866496at2759; -.
DR   PhylomeDB; P08637; -.
DR   PathwayCommons; P08637; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   SIGNOR; P08637; -.
DR   BioGRID-ORCS; 2214; 4 hits in 915 CRISPR screens.
DR   ChiTaRS; FCGR3A; human.
DR   EvolutionaryTrace; P08637; -.
DR   GeneWiki; FCGR3A; -.
DR   GenomeRNAi; 2214; -.
DR   Pharos; P08637; Tbio.
DR   PRO; PR:P08637; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P08637; protein.
DR   Bgee; ENSG00000203747; Expressed in granulocyte and 114 other tissues.
DR   ExpressionAtlas; P08637; baseline and differential.
DR   Genevisible; P08637; HS.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0019864; F:IgG binding; IEA:UniProtKB-KW.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:0018149; P:peptide cross-linking; TAS:Reactome.
DR   GO; GO:0050776; P:regulation of immune response; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   Pfam; PF13895; Ig_2; 2.
DR   SMART; SM00409; IG; 2.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; Glycoprotein;
KW   IgG-binding protein; Immunoglobulin domain; Membrane; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..16
FT                   /evidence="ECO:0000255"
FT   CHAIN           17..254
FT                   /note="Low affinity immunoglobulin gamma Fc region receptor
FT                   III-A"
FT                   /id="PRO_0000015150"
FT   TOPO_DOM        17..208
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        209..229
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        230..254
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          24..105
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          107..189
FT                   /note="Ig-like C2-type 2"
FT   CARBOHYD        56
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        63
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21768335,
FT                   ECO:0000269|PubMed:22023369"
FT   CARBOHYD        92
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        180
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21768335,
FT                   ECO:0000269|PubMed:22023369"
FT   CARBOHYD        187
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        47..89
FT                   /evidence="ECO:0000269|PubMed:21768335,
FT                   ECO:0000269|PubMed:22023369, ECO:0007744|PDB:3AY4,
FT                   ECO:0007744|PDB:3SGJ, ECO:0007744|PDB:3SGK"
FT   DISULFID        128..172
FT                   /evidence="ECO:0000269|PubMed:21768335,
FT                   ECO:0000269|PubMed:22023369, ECO:0007744|PDB:3AY4,
FT                   ECO:0007744|PDB:3SGJ, ECO:0007744|PDB:3SGK"
FT   VARIANT         66
FT                   /note="L -> H (in IMD20; dbSNP:rs10127939)"
FT                   /evidence="ECO:0000269|PubMed:23006327,
FT                   ECO:0000269|PubMed:8608639, ECO:0000269|PubMed:8609432,
FT                   ECO:0000269|PubMed:8874200"
FT                   /id="VAR_008800"
FT   VARIANT         66
FT                   /note="L -> R (in dbSNP:rs10127939)"
FT                   /evidence="ECO:0000269|PubMed:8609432"
FT                   /id="VAR_008799"
FT   VARIANT         147
FT                   /note="G -> D (in dbSNP:rs443082)"
FT                   /id="VAR_058398"
FT   VARIANT         158
FT                   /note="Y -> H (in dbSNP:rs396716)"
FT                   /id="VAR_058399"
FT   VARIANT         176
FT                   /note="F -> V (shows a higher binding capacity of IgG1,
FT                   IgG3 and IgG4; dbSNP:rs396991)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7700021, ECO:0000269|PubMed:9242542,
FT                   ECO:0000269|PubMed:9276722, ECO:0000269|Ref.3"
FT                   /id="VAR_003960"
FT   VARIANT         203
FT                   /note="F -> S (in dbSNP:rs1042206)"
FT                   /id="VAR_058400"
FT   CONFLICT        106
FT                   /note="I -> V (in Ref. 3; BAD96988/BAD97015)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        195
FT                   /note="A -> S (in Ref. 5; AAH33678)"
FT                   /evidence="ECO:0000305"
FT   STRAND          28..33
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          35..38
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          43..47
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          51..54
FT                   /evidence="ECO:0007744|PDB:3SGJ"
FT   STRAND          60..65
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          71..78
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   HELIX           81..83
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          85..89
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          100..105
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          107..112
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          116..119
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          124..130
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   HELIX           131..133
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          137..143
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          146..153
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          157..161
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   HELIX           164..166
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          168..176
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          179..182
FT                   /evidence="ECO:0007744|PDB:3AY4"
FT   STRAND          186..191
FT                   /evidence="ECO:0007744|PDB:3AY4"
SQ   SEQUENCE   254 AA;  29089 MW;  D38D178D32C67337 CRC64;
     MWQLLLPTAL LLLVSAGMRT EDLPKAVVFL EPQWYRVLEK DSVTLKCQGA YSPEDNSTQW
     FHNESLISSQ ASSYFIDAAT VDDSGEYRCQ TNLSTLSDPV QLEVHIGWLL LQAPRWVFKE
     EDPIHLRCHS WKNTALHKVT YLQNGKGRKY FHHNSDFYIP KATLKDSGSY FCRGLFGSKN
     VSSETVNITI TQGLAVSTIS SFFPPGYQVS FCLVMVLLFA VDTGLYFSVK TNIRSSTRDW
     KDHKFKWRKD PQDK
//
